PARP inhibition: PARP1 and beyond - Test2 - elhamkhani - TriplyDB

PARP inhibition: PARP1 and beyond

PARP inhibition: PARP1 and beyond

http://www.wikidata.org/entity/Q29619617

about

The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies Single cell analysis of drug distribution by intravital imaging Investigation of PARP-1, PARP-2, and PARG interactomes by affinity-purification mass spectrometry Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation Regulation of DNA-damage responses and cell-cycle progression by the chromatin remodelling factor CHD4 Poly(ADP-ribose) polymerase-1 inhibition by arsenite promotes the survival of cells with unrepaired DNA lesions induced by UV exposure Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro Emerging therapeutic roles for NAD(+) metabolism in mitochondrial and age-related disorders Functions of PARylation in DNA Damage Repair Pathways Current and emerging therapies in unresectable and recurrent gastric cancer New treatment option for ovarian cancer: PARP inhibitors Trial watch - inhibiting PARP enzymes for anticancer therapy Radioresistance of Brain Tumors Molecular Biomarkers of Pancreatic Intraepithelial Neoplasia and Their Implications in Early Diagnosis and Therapeutic Intervention of Pancreatic Cancer PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives DNA repair targeted therapy: The past or future of cancer treatment?DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer Successes and Challenges of PARP Inhibitors in Cancer Therapy Chemical Disruption of Wnt-dependent Cell Fate Decision-making Mechanisms in Cancer and Regenerative Medicine Olaparib in the management of ovarian cancer Poly(ADP-Ribose) Polymerase 1: Cellular Pluripotency, Reprogramming, and Tumorogenesis Repair of oxidative DNA damage and cancer: recent progress in DNA base excision repair Improving the efficacy of chemoradiation with targeted agents Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors Pleiotropic cellular functions of PARP1 in longevity and aging: genome maintenance meets inflammation PARPs and the DNA damage response The role of PARP in DNA repair and its therapeutic exploitation Advances in using PARP inhibitors to treat cancer Structure and function of the ARH family of ADP-ribosyl-acceptor hydrolases DNA Damage and Pulmonary Hypertension The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy Targeting DNA damage response in cancer therapy PARP inhibition in leukocytes diminishes inflammation via effects on integrins/cytoskeleton and protects the blood-brain barrier.Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review PARP1 gene knock-out increases resistance to retinal degeneration without affecting retinal function.Poly(ADP-ribose) polymerase-1 inhibition in brain endothelium protects the blood-brain barrier under physiologic and neuroinflammatory conditions.Aag DNA glycosylase promotes alkylation-induced tissue damage mediated by Parp1 Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent.Crystal Structures of Poly(ADP-ribose) Polymerase-1 (PARP-1) Zinc Fingers Bound to DNA: STRUCTURAL AND FUNCTIONAL INSIGHTS INTO DNA-DEPENDENT PARP-1 ACTIVITY

P2860

Q21129302-5A9B297B-B5BD-4BF7-88D6-4BBE50A6FCAB Q21133568-40236392-E0CE-42E6-A97B-5688C971BBA6 Q21245636-3436D5EF-B90E-418F-9002-9EEEFF1121A2 Q24293084-E814402C-0F68-4461-8B05-4ED62591608E Q24294656-74AA5778-4E13-420A-B405-FB8E3308D11F Q24595686-7DC222C9-0811-4B17-A7AE-4703B15A57AF Q24615499-19FB469A-212C-4D86-BD4D-C166DB0C2111 Q26741300-1A741FE5-00FA-431F-9BC0-F16114285E1B Q26744796-55ABA308-178F-4BDF-A6C0-ABC2D3618CD7 Q26745453-3B0E715C-8D6B-4501-A070-447FA53DBE7F Q26745614-B6FCE8CB-7927-462B-8D0E-536D669749C6 Q26745673-E774B44F-43D0-4A0C-87CD-D0591B77F08E Q26752579-19F16159-3B1D-4B86-BE00-C0F1509C0C68 Q26765241-57AD6AAE-2FBC-4A1A-9980-B424844296B7 Q26768661-5D5516CD-5BF2-46CD-A7CC-7F0D1D5F358F Q26768679-26853E7A-F82E-4483-BF11-76BA8F7DA577 Q26776513-2C83A4E5-2589-4E4A-8672-DAF93DD8CC6D Q26777131-671DEE14-0C83-4FEF-BB68-7B71915D29CE Q26796673-F3749A86-2D8C-4E06-8B40-C2D3CBBD69E8 Q26797166-B95ABAA5-3AD4-4EB0-8C90-99DC29B753DC Q26800013-01AE769A-F981-4679-96DF-225709D81BA4 Q26822957-E57C680E-0EC0-4C6E-B474-98A6855E40C1 Q26850193-008A1811-B9FF-4FE8-9E44-DB3FAFFFF2D8 Q26851765-B3D102DE-BF11-463A-A520-28FDF00E20E2 Q26852274-310568C7-A099-4D23-9FE5-0A03DCC3A2ED Q26858894-A8BA8905-F13A-47C1-B476-EAF5A913FC46 Q26859010-67ABC619-A7A5-4456-8D74-02CC717F962B Q27002399-C8BF8A44-B6F7-471E-ABA3-6DD80A11695C Q27003972-716F1927-F312-4838-8CFA-DFB5C6A78AEF Q27004584-625C7723-B9F7-40E5-925F-30F21F67B28F Q27005594-A733C35E-A73A-48A2-8725-0A2FFF57C2A5 Q27010084-4B8196C5-4545-4978-B404-1B7CD1C6447B Q27023204-68FB4AFF-B67D-44BE-A172-786913F16B88 Q27303034-B5E9D435-1A0B-4069-837D-7A88BD29AECF Q27304386-91C5B929-D861-4B06-995F-DFD92C1B6882 Q27312275-606792F1-201F-4EC4-8D81-DF3D501DD64C Q27321704-B92AB17F-CC5E-4BD1-8214-613F7C6AE41E Q27323759-B807A9BA-729B-4AA3-93A9-6FFBCB709288 Q27347956-A870A9BB-0CFF-41FE-A47E-AA68C4038702 Q27666573-D43F29C8-68FA-42A4-9F10-18A48BD8C66A

P2860

PARP inhibition: PARP1 and beyond

http://www.wikidata.org/entity/Q29619617

description

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

artículu científicu espublizáu en 2010

@ast

im April 2010 veröffentlichter wissenschaftlicher Artikel

@de

scientific article (publication date: April 2010)

@en

wetenschappelijk artikel (gepubliceerd in 2010-04)

@nl

наукова стаття, опублікована у квітні 2010

@uk

مقالة علمية (نشرت في أبريل 2010)

@ar

name

PARP inhibition: PARP1 and beyond

@ast

PARP inhibition: PARP1 and beyond

@en

type

label

PARP inhibition: PARP1 and beyond

@ast

PARP inhibition: PARP1 and beyond

@en

prefLabel

PARP inhibition: PARP1 and beyond

@ast

PARP inhibition: PARP1 and beyond

@en

P1433

Q29619617-147AE52B-8F11-4D1F-A963-11C5B563DE4F

P1476

Q29619617-BAE618B9-0D31-479B-8F43-8C03EC0ACC84

P2093

Q29619617-4CCDF0C5-A404-4FF5-86B4-83CF3F694659

Q29619617-90847D61-14EA-415D-A668-59632FE7075B

Q29619617-A1E38E51-7ED0-44E0-8A75-99A0F24E205E

Q29619617-E3B0B687-F41A-4DB7-B606-B23B7DE86E9C

Q29619617-F63A49FE-97EF-4971-B068-02C2D6A43891

P2860

Q29619617-001AB5D9-4F42-412D-AC97-AA8158D8652D

Q29619617-01C419AD-2A59-45BE-A5BF-45A0AFB3CB40

Q29619617-0880F8E1-7ACB-43F5-A58E-9E959CDFA469

Q29619617-0D778B57-B679-4F8B-A898-BFDB82D9D08A

Q29619617-0EF062E6-EE3E-446B-A504-BE05FA70C9D0

Q29619617-0F78B86A-DB7A-4AEC-84A8-7A78834BA678

Q29619617-142C9651-29E3-4B81-9840-DD837EB4A8D9

Q29619617-14702758-00F2-47CD-AE24-933C36FF9D7C

Q29619617-16D489B1-E068-4FDD-9285-1C853F6C67C3

Q29619617-19671503-DD8C-43F2-976C-536B52ECF6D2

P2888

Q29619617-BF76A3AC-BA98-4792-A05D-76C93C8220D2

P304

Q29619617-5177D3C5-049B-4318-BAA5-CD0F017DE374

P31

Q29619617-5DE80A33-C74C-4604-80FF-3813FD88AA2B

P3181

Q29619617-AA90436D-8BC4-4BF9-ACFC-3E48177F5108

P356

Q29619617-06E32831-B311-45E3-9D88-73C14E68D4AF

P407

Q29619617-6E001EF8-9B4B-4A44-886F-0A9942FF8D82

P433

Q29619617-771D86BC-1C54-4304-9C6C-F79D8E85ABF1

P478

Q29619617-DFEC358E-51AF-4336-86B2-C21ABA39B8BF

P577

Q29619617-DB6CEE05-7904-411D-A57F-5E8E2C16A528

P5875

Q29619617-5B051F9B-9351-43BE-A87C-F48642979CFC

P6179

Q29619617-1DF33979-B67D-48FD-8920-544C8DF4D0ED

P698

Q29619617-7EA6142E-F95A-457F-8601-9C404EBCC669

P932

Q29619617-CFB8B90C-2D5A-4D31-99D9-1A9AE9C6ECE1

P3181

P356

P1433

Nature Reviews Cancer

P1476

PARP inhibition: PARP1 and beyond

@en

P2093

Hendzel MJ

http://www.w3.org/2001/XMLSchema#string

Kaufmann SH

http://www.w3.org/2001/XMLSchema#string

Patel A

http://www.w3.org/2001/XMLSchema#string

Poirier GG

http://www.w3.org/2001/XMLSchema#string

Rouleau M

http://www.w3.org/2001/XMLSchema#string

P2860

Vault poly(ADP-ribose) polymerase is associated with mammalian telomerase and is dispensable for telomerase function and vault structure in vivo

Protein requirements for sister telomere association in human cells

Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling

Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1

Zinc binding catalytic domain of human tankyrase 1

XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage

Tankyrase-2 oligomerizes with tankyrase-1 and binds to both TRF1 (telomere-repeat-binding factor 1) and IRAP (insulin-responsive aminopeptidase)

Understanding and treating triple-negative breast cancer

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

Poly(ADP-ribosyl)ation directs recruitment and activation of an ATP-dependent chromatin remodeler

P2888

P304

293-301

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

580278

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NRC2812

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41722345

http://www.w3.org/2001/XMLSchema#string

P6179

1040684149

http://www.w3.org/2001/XMLSchema#string

P698

20200537

http://www.w3.org/2001/XMLSchema#string

P932

2910902

http://www.w3.org/2001/XMLSchema#string